Citadel Advisors
TNXP icon

Citadel Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Citadel Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$353K Buy
+25,700
New +$396K ﹤0.01% 10099
2016
Q3 		– Hold
0
– -$20K – 7774
2016
Q2 		– Hold
0
– – – 6606
2016
Q1 		– Hold
0
– -$35K – 7958
2015
Q4 		– Hold
0
– – – 7567
2015
Q3 		– Hold
0
– – – 8438
2015
Q2 		– Hold
0
– – – 7689
2015
Q1 		– Hold
0
– – – 7358
2014
Q4 		– Hold
0
– – – 7857

Other funds holding TNXP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JHC
Jones Hill Capital New York $466M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's TNXP Position: Q1 2026 in Review

Citadel Advisors opened a new position in Tonix Pharmaceuticals (TNXP) in Q1 2026: 468,712 shares worth $6.44M. The stake represents ﹤0.01% of the portfolio and ranks #3936 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in TNXP as recently as Q2 2025.

Citadel Advisors first reported a position in TNXP in Q2 2020 and has held it in 7 quarters since. 81 funds tracked by Wall St. Rank hold TNXP as of Q1 2026.

  • Citadel Advisors held 468,712 shares of Tonix Pharmaceuticals worth $6.44M as of Q1 2026.
  • Tonix Pharmaceuticals was a new Citadel Advisors position in Q1 2026.
  • Tonix Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3936 holding.
  • Citadel Advisors first reported a position in Tonix Pharmaceuticals in Q2 2020 and has held it in 7 quarters since.
  • 81 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.